Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer

Journal of Clinical Oncology

Volumn 20, Issue 2, 2002, Pages 582-587

  Schilsky, Richard L ^a   Bertucci, Donna ^a   Vogelzang, Nicholas J ^a   Kindler, Hedy L ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL; GEMCITABINE;

ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SOLID TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; PANCREATIC NEOPLASMS; STOMATITIS; TREATMENT OUTCOME;

EID: 0037080146     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.20.2.582     Document Type: Article

References (20)

1. Pharmacology and clinical studies of capecitabine
2. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissue
3. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors
4. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts
5. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma
6. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
7. Capecitabine, an oral fluoropyrimidine with substantial activity in advanced colorectal cancer: Results of a randomized phase II study
8. Action of 2,2-difluoro 2-deoxycytidine on DNA synthesis
9. Inhibition of ribonulceotide reduction in CCRF-CLM cells by 2, 2-difluoro-2-deoxycytidine
10. Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro 2-deoxyuridine in HT-29 colon cancer cells
11. Synergistic interactions of gemcitabine and 5-FU in colon cancer cells
12. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: A potentially broadly active regimen for advanced solid tumor malignancies
13. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer
14. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies
15. A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent and/or metastatic solid tumors
16. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer
17. A phase I trial of gemcitabine and infusional 5-fluorouracil in patients with refractory solid tumors
18. A phase II trial of gemcitabine in combination with 5-fluorouracil and folinic acid in patients with chemonaive advanced pancreatic cancer
19. Phase II study of gemcitabine and continuous intravenous infusion of 5-fluorouracil in advanced pancreatic cancer: A University of Chicago phase II consortium study
20. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase and thymidine phosphorylase